Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

NEW YORK – Dermatologic diagnostics company Castle Biosciences said on Tuesday that it has been awarded a five-year US Federal Supply Schedule contract by the Veterans Health Administration for its DecisionDx-Melanoma gene expression profile test.

Financial terms of the contract were not disclosed.

The VHA is a component of and implements the healthcare program for US veterans through the US Department of Veterans Affairs. The contract, which became effective on Aug. 15, provides greater access to DecisionDx-Melanoma for veterans being treated through the VHA, as well as active duty service members and their families seeking medical treatment through the military's health system, Friendswood, Texas-based Castle Bio said.

"We believe that adding the personalized genomic information provided by our DecisionDx-Melanoma test to traditional clinical and pathology factors can help clinicians make improved treatment decisions for their [skin cancer] patients," Castle Bio CEO Derek Maetzold said in a statement. "This contract provides veterans and active-duty service members treated in VA and [military health system] medical centers greater access to our test, allowing them to incorporate DecisionDx-Melanoma into their management plans."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.